Significant changes may have occurred in France, in the population that developed malaria after travel in endemic areas, which implies that preventative strategies need to be adapted.
The Food and Drug Administration has granted an investigational treatment for severe malaria Breakthrough Therapy designation.
Only 1.0 percent of reported cases of spotted fever rickettsioses (SFR) meet the confirmed case definition.
Jonathan Miner, MD, PhD, and Karin Nielsen-Saines, MD, MPH, discuss the latest insights about neurologic complications of ZVI and knowledge gaps that still exist in this field.
The TIDES trial is investigating the safety and efficacy of 2 doses of TAK-003 in preventing dengue fever caused by any of the 4 dengue virus serotypes.
A malaria transmission-blocking vaccine, Pfs25H-EPA in Alhydrogel®, was well tolerated and safe and induced significant blockage of parasite transmission, but this activity was only seen at peak titers after 4 vaccine doses.
